Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, said it received approval from the Food and Drug Administration to begin a Phase II trial using spinal cord-derived human neural stem cells to treat amyotrophic lateral sclerosis .
http://thedailyrecord.com/2013/04/17/fda-oks-neuralstems-als-clinical-trial/
http://thedailyrecord.com/2013/04/17/fda-oks-neuralstems-als-clinical-trial/
No comments:
Post a Comment